Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 15/20 | 0.62 |
| ▸ | LCK | P06239 | 14/20 | 0.62 |
| ▸ | KDR | P35968 | 9/20 | 0.62 |
| ▸ | JAK3 | P52333 | 9/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978094 | 0.80 | TNK2 (0.72) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL737611 | 0.80 | TNK2 (0.52) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL13436256 | 0.80 | TNK2 (0.67) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL1786338 | 0.79 | KDM4E (0.61) | TNK2KDR | |
| SCHEMBL2968470 | 0.77 | TNK2 (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3566207 | 0.77 | LCK (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL2971893 | 0.77 | TNK2 (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL14923117 | 0.77 | AURKA (0.48) | TNK2EGFRSRC | |
| SCHEMBL3572069 | 0.76 | LCK (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL2967785 | 0.76 | TNK2 (0.76) | TNK2LCKKDRJAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | TNK2 1075/4885LCK 18/4885KDR 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.